Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
9(82%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
45%
Ph phase_2
4
36%
Ph phase_3
2
18%

Phase Distribution

5

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
5(45.5%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

9

trials recruiting

Total Trials

11

all time

Status Distribution
Active(9)
Completed(1)
Terminated(1)

Detailed Status

Recruiting6
Active, not recruiting3
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
9
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (45.5%)
Phase 24 (36.4%)
Phase 32 (18.2%)

Trials by Status

withdrawn19%
recruiting655%
completed19%
active_not_recruiting327%

Recent Activity

9 active trials
Showing 5 of 11
recruitingphase_1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515
withdrawnphase_1

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

NCT06767956
recruitingphase_1

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

NCT06209619
active_not_recruitingphase_3

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129
recruitingphase_1

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

NCT07018752
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05169515Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting
NCT06767956Phase 1

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Withdrawn
NCT06209619Phase 1

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

Recruiting
NCT06356129Phase 3

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Active Not Recruiting
NCT07018752Phase 1

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting
NCT06834373Phase 2

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Recruiting
NCT06425302Phase 2

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Active Not Recruiting
NCT06911502Phase 3

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting
NCT05788081Phase 2

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Active Not Recruiting
NCT06271057Phase 2

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Recruiting
NCT06363630Phase 1

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11